塞来昔布防治大鼠创伤性骨化性肌炎的研究  

Study of celecoxib in the prevention and treatment of traumatic myositis ossificans in rats

作　　者：曾荣东[1] 柳明忠[1] 陈巧凤[1] 陈小青[1] 许志通[1] 张志珊[2] 郑锦阳[3] 连涛[4] 

机构地区：[1]福建医科大学附属泉州市第一医院骨科,福建泉州362000 [2]福建医科大学附属泉州市第一医院检验科,福建泉州362000 [3]福建医科大学附属泉州市第一医院病理科,福建泉州362000 [4]福建医科大学附属泉州市第一医院影像科,福建泉州362000

出　　处：《中国临床药理学杂志》2017年第23期2401-2403,共3页The Chinese Journal of Clinical Pharmacology

基　　金：福建省自然科学基金资助项目(2016J01610)

摘　　要：目的研究塞来昔布防治大鼠创伤性骨化性肌炎(TMO)的疗效及其可能的相关分子机制。方法制备TMO SD大鼠模型,将40只模型大鼠随机分为对照组和实验组,每组各20只。实验组予以10 mg·kg-1·d-1塞来昔布灌胃给药,qd;对照组予以等量0.9%Na Cl灌胃给药,qd。2组大鼠均给药10周。用X线片检查新骨形成情况,用免疫酶联反应法检测血清中肿瘤坏死因子-α(TNF-α)和白细胞介素-6(IL-6)以及跟腱组织中骨形态发生蛋白-4(BMP-4)的表达情况。结果术后第5周,实验组和对照组的新骨形成率分别为35.00%(7只/20只)和70.00%(14只/20只),TNF-α水平分别为(73.6±15.9)和(101.5±17.3)ng·L^(-1),IL-6水平分别为(33.6±5.8)和(52.8±7.2)ng·L^(-1),差异均有统计学意义(均P<0.05)。术后第10周,实验组和对照组的新骨形成率分别为65.00%(13只/20只)和95.00%(19只/20只),TNF-α水平分别为(55.8±12.7)和(81.7±15.6)ng·L^(-1),BMP-4分别为(4.5±0.3)和(5.3±0.2)μg·L^(-1),差异均有统计学意义(均P<0.05)。结论塞来昔布对TMO有较好的防治作用,其机制可能与抑制炎症水平及下调BMP-4表达有关。Objective To study the efficacy and possible molecular mechanisms of celecoxib on the prevention and treatment of traumatic myositis ossificans（ TMO） in rats. Methods TMO SD rats were prepared,and 40 rats were randomly divided into control group and test group,20 rats in each group. The test group was given 10 mg·kg^（-1）·d-1 celecoxib by intragastric administration,qd,and the control group was given an amount of 0. 9% Na Cl by intragastric administration,qd. Two groups of rats were given 10 weeks. New bone formation of two groups was detected by X ray examination. Enzyme-linked immunosorbent assay（ ELISA）was used to detect the expressions level of tumor necrosis factor-α（ TNF-α）,interleukin-6（ IL-6） and bone morphogenetic protein-4（ BMP-4）. Results At the fifth week after operation,the new bone formation in the test group and the control group were 35. 00%（ 7 cases/20 cases） and 70. 00%（ 14 cases/20 cases）,TNF-α levels were（ 73. 6 ± 15. 9） and（ 101. 5 ± 17. 3） ng·L-1,and IL-6 levels were（ 33. 6 ± 5. 8） and（ 52. 8 ± 7. 2） ng·L-1,the differences were statistically significant（ all P〈0. 05）. At the tenth week after operation,the new bone formation in the test group and the control group were 65. 00%（ 13 cases/20 cases） and 95. 00%（ 19 cases/20 cases）,TNF-α levels were（ 55. 8 ± 12. 7） and（ 81. 7 ± 15. 6）ng·L-1,and BMP-4 levels were（ 4. 5 ± 0. 3） and（ 5. 3 ± 0. 2） ng · L-1,the differences were statistically significant（ all P〈0. 05）. Conclusion Celecoxib has a good preventive and therapeutic effect on TMO,and its mechanism may be related to the inhibition of the level of inflammation and down-regulation of BMP-4 expression.

关 键 词：塞来昔布 创伤性骨化性肌炎 炎症因子 骨形态发生蛋白-4 

分 类 号：R971.1[医药卫生—药品]